

# Contributions of mean and shape of blood pressure distribution to global trends and variations in raised blood pressure

NCD Risk Factor Collaboration (NCD-RisC)

Address correspondence to Majid Ezzati (majid.ezzati@imperial.ac.uk)

## Abstract

Both shifts in the entire distribution of blood pressure and changes in its high-blood-pressure tail could change the prevalence of raised blood pressure. We pooled 981 population-based studies with 11.6 million participants, and used a generalised linear mixed model, to examine the contributions of the two drivers to worldwide trends in prevalence from 1985-1994 to 2005-2016. In 2005-2016, at the same level of population mean SBP and DBP, men and women in south Asia would have the highest prevalence of raised blood pressure, and those in the high-income Asia Pacific region would have the lowest. In most region-sex-age groups where the prevalence of raised blood pressure declined, one half or more of the decline was due to the decline in mean blood pressure. Where prevalence of raised blood pressure increased, the change was entirely driven by increasing mean blood pressure, offset partly by the change in the prevalence-mean association.

## Introduction

Raised blood pressure, commonly defined as systolic blood pressure (SBP)  $\geq 140$  mmHg or diastolic blood pressure (DBP)  $\geq 90$  mmHg, is used to identify high-risk individuals (1-3). Globally, one in four men and one in five women, totalling 1.13 billion adults, had raised blood pressure in 2015 (4). One of the global non-communicable disease (NCD) targets adopted by the World Health Assembly in 2013 is to lower the prevalence of raised blood pressure by 25% compared to its 2010 level by 2025 (5).

26

27 The prevalence of raised blood pressure varies substantially across and within regions and  
28 countries, with age-standardised adult prevalence in 2015 ranging from 20% in the high-  
29 income Asia Pacific region to 33% in central and eastern Europe for men, and from 11% in  
30 the high-income Asia Pacific region to 28% in sub-Saharan Africa for women (4). Prevalence  
31 has declined substantially in high-income regions for decades and is also declining in some  
32 middle-income regions; it has been stable or has increased in other low- and middle-income  
33 regions (4).

34

35 Blood pressure is a multifaceted trait, affected by genes, foetal and early childhood nutrition  
36 and growth (6), adiposity (7, 8), diet (especially sodium and potassium intakes) (7, 9, 10),  
37 alcohol use (8, 11), smoking (12), physical activity (8, 13), air pollution (14), lead (15), noise  
38 (16), psychosocial stress (17), and the use of blood pressure lowering medicines. Changes in  
39 some of these factors, for example increase in body-mass index (BMI) and better nutrition in  
40 childhood and adolescence, can shift the entire population distribution of blood pressure, and  
41 hence change its mean as well as the prevalence of raised blood pressure. In contrast, the use  
42 of antihypertensive medicines and lifestyle change to reduce blood pressure in those with  
43 elevated levels would reduce the prevalence of raised blood pressure by acting on the high-  
44 blood-pressure tail of the distribution, and hence change the shape of the distribution with a  
45 relatively small impact on its mean. An important question that can inform strategies for  
46 meeting the global target and reducing the burden of raised blood pressure, is to what extent  
47 regional differences and changes over time in the prevalence of raised blood pressure are  
48 driven by variations in the mean SBP and DBP versus by the shape of the distribution. We  
49 used a database of population-based studies with global coverage conducted over three

decades to investigate contributions of population mean and high-blood-pressure individuals to worldwide trends and variations in raised blood pressure.

## Results

We used data from 981 population-based studies with 11,618,576 participants (Supplementary Table 1), of whom 10,630,495 were aged 20-79 years and satisfied the above inclusion criteria. 380 studies were from the high-income western region, 101 each from central and eastern Europe and east and southeast Asia, 98 from central Asia, Middle East and north Africa, 80 from sub-Saharan Africa, 76 each from high-income Asia Pacific and Latin America and the Caribbean, 36 from south Asia and 33 from Oceania. The individual-level data were summarised into 7,600 age-sex specific pairs of mean and prevalence of raised blood pressure.

The coefficients of the regression models are listed in Supplementary Tables 2 and 3. Together, mean SBP and DBP, decade, age group and region explained most of the variation in the prevalence of raised blood pressure, evidenced by the high pseudo- $R^2$  statistics of 0.952 for women and 0.932 for men.

The prevalence of raised blood pressure decreased substantially from 1985-1994 to 2005-2016 in the two high-income regions and central and eastern Europe in both men and women across all ages (Figure 2) (4). It also decreased in Latin America and the Caribbean, and central Asia, Middle East and north Africa, and marginally in men in sub-Saharan Africa. Over the same period, mean SBP and mean DBP decreased in these regions and sexes, except in men in sub-Saharan Africa, whose mean SBP and DBP increased, and in men in central Asia, Middle East and north Africa, whose mean SBP and DBP were unchanged. In 2005-

2016, the age-standardised prevalence of raised blood pressure in people aged 20-49 years ranged from 4% (95% credible interval: 3%-6%) in the high-income Asia Pacific to 16% (13%-19%) in sub-Saharan Africa in women, and from 14% (11%-17%) in the high-income Asia Pacific to 25% (21%-30%) in central and eastern Europe in men. In those aged 50-79 years, the range was from 31% (26%-36%) in high-income Asia Pacific to 56% (52%-61%) in sub-Saharan Africa in women, and from 40% (36%-43%) in the high-income western region to 57% (51%-63%) in central and eastern Europe in men.

Although in 2005-2016 the ranking of regions in terms of prevalence of raised blood pressure was largely the same as that of the mean, especially for women, inter-region differences in prevalence were not entirely due to those of mean blood pressure. Rather, some regions had an excess prevalence compared to what would be expected based on their mean, and others a lower prevalence compared to what would be expected based on their mean. At the same level of population mean SBP and DBP as that of the world as a whole, men and women in south Asia would have the highest prevalence of raised blood pressure, about 2-4 percentage points higher than the world average in different age and sex groups (Figure 3). Next highest would be in central Asia, Middle East and north Africa, followed by that in Latin America and the Caribbean. In contrast, at the same level of population mean SBP and DBP as that of the world as a whole, high-income Asia Pacific would have the lowest prevalence, followed by central and eastern Europe, with prevalence about 2-4 percentage points lower than the world average across different age and sex groups. The ordering of regions in terms of excess prevalence was similar between men and women.

In most regions, sex and age groups that experienced a decline in the prevalence of raised blood pressure, the decline in mean blood pressure was the main driver of the decline in

prevalence (Figure 4). The main exceptions to this distributional shift were men in sub-Saharan Africa and in central Asia, Middle East and north Africa whose mean blood pressure increased or remained unchanged while prevalence declined slightly. Further, in men in Latin America and the Caribbean, change in prevalence-mean association contributed marginally more to prevalence decline than did the decline in mean blood pressure. Elsewhere, the decline in mean blood pressure accounted for about one half or more of the decline in the prevalence of raised blood pressure, with a larger contribution where mean blood pressure declined more, typically in high-income regions. Change in the prevalence-mean association, which represents change in the high-blood-pressure tail of the distribution, was responsible for the majority of the remainder of change in prevalence, and for its entirety among men in sub-Saharan Africa and in central Asia, Middle East and north Africa. The contribution of change in prevalence-mean association was larger in those aged 50-79 years than in those aged 20-49 years in most regions, especially for women.

The prevalence of raised blood pressure increased among men and women in Oceania and south Asia, and among women in sub-Saharan Africa and men in east and southeast Asia. The increase was driven entirely by rise in mean blood pressure, offset partly by the change in the prevalence-mean association. Prevalence of raised blood pressure remained largely unchanged among women in east and southeast Asia, due to opposing effects of increasing mean and the decrease brought by the changes in prevalence-mean association.

## **Discussion**

We found that the trends and geographical variations in the prevalence of raised blood pressure are largely driven by shifts in the distribution of blood pressure in whole populations, rather than by the shape of the distribution. There was nonetheless contribution from having

fewer high-blood-pressure individuals at the same level of population mean SBP and DBP, generally towards lowering the prevalence of raised blood pressure over time, especially in older age groups.

Rose and Day (18) and Laaser *et al* (19) used data from the Intersalt Study and from population-based studies in Germany, respectively, and found a strong association between prevalence of raised blood pressure and its mean, as we did, but neither analysis had sufficient data to quantify how the association varied in relation to age, time period or region as was done here. An analysis of data from the multi-country MONICA Project (20) found that the upper percentiles of blood pressure distribution changed as much as its mean in some communities, and by a larger amount in others. The authors concluded that the decline in blood pressure is mostly a population phenomenon but there was no detailed quantification of the contribution, especially in relation to age, time period or region as was done here with substantially more data. Downward shifts in the whole blood pressure distribution over time have also been reported in a few high-income countries (21-28), with some studies also finding a larger decline in the upper tail than in the mean of the blood pressure distribution which is consistent with our results.

The strengths of our study include presenting the first global analysis of how much population mean and high-blood-pressure individuals have contributed to worldwide trends and variations in raised blood pressure, using a large global database with data from different regions and over time, and using methods that allowed the prevalence-mean association to vary by sex, age group, time period and region. Despite using the most comprehensive global collection of population-based studies to date, some regions had limited data, especially early in our analysis period. Further, there have been changes over time in devices used for

measuring blood pressure in health surveys, with standard mercury sphygmomanometers replaced by random-zero sphygmomanometers and more recently digital oscillometric devices. These changes are unlikely to have affected our regional comparisons, and would only affect prevalence-mean association over time if they had differential effects at high versus low blood pressure.

Although we found that changes in the prevalence of raised blood pressure have been mostly due to whole-distribution shifts, the behavioural, nutritional and environmental drivers of this shift remain uncertain. In high-income countries, the decline in blood pressure has occurred despite the rise in BMI (29), which is an established risk factor for high blood pressure, but how the concurrent and at times larger rise in BMI in low- and middle-income countries may be affecting blood pressure is unclear. Salt intake has declined in China (30) and possibly in some high-income countries (31-33), but has not changed in other countries where blood pressure has declined (34-38). Similarly, prevalence of smoking has declined in most high-income countries and in some middle-income countries but remains high or is increasing in other low- and middle-income regions (39). Other potential population-wide drivers of the decline in mean blood pressure which tend to improve with social and economic development include year-round availability of fruits and vegetables, which might increase the amount and regularity of their consumption (40); central heating at home and work which would lower winter blood pressure (41-43); and improvements in early childhood and adolescent nutrition, as seen in greater height in successive birth cohorts when they reach adulthood (44). A role for such distal determinants with life-course impacts is strengthened by the fact that blood pressure is also decreasing in adolescents in high-income countries and possibly some middle-income countries (45-49).

While these determinants act to lower mean blood pressure, better developed health systems are more effective in identifying and treating high-blood-pressure individuals, which would change the tail of the distribution without a major impact on its mean. The role of treatment in reducing the prevalence of high blood pressure has become increasingly important as clinical guidelines have lowered the threshold for diagnosing and treating hypertension, e.g., from having a SBP of 160 mmHg or DBP of 95 mmHg in the 1970s (50) to a SBP of 140 mmHg or DBP of 90 mmHg now (3, 51). Over time, a larger share of people with raised blood pressure are treated in high-income countries (21, 52-59), and in some middle-income countries (60-65). Further, there has been improvements in effectiveness of treatment over time, leading to better control of those with hypertension. It may also be the case that changes in some risk factors, e.g., lower salt intake, have larger benefits for people whose blood pressure is high compared to those with low blood pressure (9), hence changing the high-blood-pressure tail of the distribution as well as its mean.

Our results demonstrate that changes in blood pressure both at the population and individual level have contributed to lowering raised blood pressure. What factors have spurred the former over the past few decades, however, remain largely unclear, and may be related to societal changes in nutrition, housing, and health systems arising from social and economic development and technological progress. They also demonstrate the need for data that go beyond identifying the causes of low or high blood pressure, but also help measure how these factors change over time in worldwide populations. Learning about these factors would inform programmes that can help reverse the rise in the prevalence of raised blood pressure or accelerate its decline in low- and middle-income nations, where prevalence remains the highest, more effectively.



## Methods

### *Study design*

We first used population-based data to estimate the association between the prevalence of raised blood pressure, defined as SBP  $\geq$ 140 mmHg or DBP  $\geq$ 90 mmHg, and population mean SBP and DBP among men and women aged 20 to 79 years in nine regions of the world from 1985 to 2016. Our statistical model, described below, allowed the prevalence of raised blood pressure *at any level of mean SBP and DBP* to differ by age group, region and time period. We then used the fitted association to estimate the contributions of changes in the population mean blood pressure versus in the shape of its distribution (represented by how the prevalence-mean association varied over region and time) to the changes in the prevalence of raised blood pressure in different regions.

### *Data sources*

We used data from NCD Risk Factor Collaboration (NCD-RisC) database, which contains studies that had measured blood pressure in representative samples of the national populations, or of one or more subnational regions and communities. Our methods for identifying and accessing data sources, and the inclusion and exclusion criteria, are described in a recent publication on blood pressure trends (4). Here, we analysed data collected from 1985 to 2016 on men and women aged 20-79 years, in 10-year age groups from 20-29 years to 70-79 years. We excluded data points which did not cover complete ten-year age groups, e.g. those in people aged 25-29 years or 60-64 years, to avoid bias in the estimated associations.

### *Statistical methods*

We calculated mean SBP, mean DBP and prevalence of raised blood pressure by sex and 10-year age group in each study, taking into account complex survey design and survey sample weights, where relevant. We excluded age-sex groups with <25 participants, because their means and prevalence have larger uncertainty. We then estimated the relationship between the prevalence of raised blood pressure and mean, using a generalised linear mixed model, shown in the equation (where  $\varepsilon$  is the error term), separately by sex. We used a probit specification because it provided a better fit to the data than a simple linear or logit model. The model included age group (10-year age groups from 20-29 to 70-79) and the decade when the data were collected (1985-1994, 1995-2004 or 2005-2016). We also included interactions between age group and mean blood pressure, between decade and mean blood pressure, and among these three terms, which allowed the prevalence-mean association to vary by age group and over time. We included regional random intercepts to account for the differences in prevalence at any level of mean SBP and DBP by region. The regions, used in previous analyses of cardiometabolic risk factors (4, 44, 66), were: central and eastern Europe; central Asia, Middle East and north Africa; east and southeast Asia; high-income Asia Pacific; high-income western countries; Latin America and the Caribbean; Oceania; south Asia; and sub-Saharan Africa. Countries in each region are listed in Supplementary Table 4. The models were fitted using a probit link function in statistical software R. Goodness of fit of the models was assessed by McFadden's pseudo- $R^2$ , which represents the proportional reduction in error variance, and is defined as one minus the ratio of the log-likelihood of the model and that of the null model (i.e. an intercept-only model) (67).

Prevalence of raised blood pressure

$$= \text{Probit}^{-1} ( \beta_0 + \beta_1 \text{Mean}_{SBP} + \beta_2 \text{Mean}_{DBP} + \beta_3 \text{Age\_group} + \beta_4 \text{Decade} \\ + \beta_5 \text{Age\_group} \cdot \text{Decade} + \beta_6 \text{Mean}_{SBP} \cdot \text{Age\_group} + \beta_7 \text{Mean}_{DBP} \cdot \text{Age\_group} )$$

$$\begin{aligned}
& + \beta_8 \text{Mean}_{SBP} \cdot \text{Decade} + \beta_9 \text{Mean}_{DBP} \cdot \text{Decade} \\
& + \beta_{10} \text{Mean}_{SBP} \cdot \text{Age\_group} \cdot \text{Decade} + \beta_{11} \text{Mean}_{DBP} \cdot \text{Age\_group} \cdot \text{Decade} \\
& + \text{Random\_intercept}_{Region} + \varepsilon )
\end{aligned}$$

We used the fitted regression to quantify how much differences across regions and changes over time in the prevalence of raised blood pressure were driven by differences/changes in mean SBP and DBP, versus by differences/changes in the prevalence-mean association across region and over time. We first used the age-sex-specific global mean SBP and DBP in 2010 (~mid-point of 2005-2016 period) in the fitted association, and estimated the prevalence of raised blood pressure by region. The age-sex-specific mean SBP and DBP values were taken from a recent comprehensive analysis of worldwide trends in blood pressure (4). We report the differences between the predicted regional raised blood pressure prevalence and that of the world as a whole. These differences measure how much prevalence would vary across regions – due to geographical variations in the shape of blood pressure distribution – if they had the same population mean blood pressure.

We then decomposed total change in prevalence of raised blood pressure from 1985-1994 to 2005-2016 into contributions of change in mean SBP and DBP, change in the shape of prevalence-mean association, and interaction of the two. The contribution of change in mean was estimated by allowing mean SBP and DBP for each age, sex, and region to change over time, while keeping the decade variable fixed at 1985-1994. The contribution of change in association was estimated by setting mean SBP and DBP to their 1990 levels (mid-year of 1985-1994) for each age, sex, and region, and allowing the decade variable to change. The interaction of the two factors is the difference between total change in prevalence and the

sum of the above two components. The three components are schematically shown in Figure 1.

All analyses were done separately for men and women. Results were calculated by 10-year age groups and then aggregated into two age bands, 20-49 years and 50-79 years, by taking weighted average of age-specific results; weights from the WHO standard population were used.

## **Acknowledgements**

M.E. was awarded funding to carry out the research from the Wellcome Trust. We thank WHO country and regional offices and World Heart Federation for support in data identification and access.

## **Author contributions**

M.E. designed the study and oversaw research. Members of the Country and Regional Data Group collected and reanalysed data, and checked pooled data for accuracy of information about their study and other studies in their country. B.Z. and M.D.C. led data collection. B.Z. and J.B. led the statistical analysis. B.Z. prepared results. Members of the Pooled Analysis and Writing Group collated data, checked all data sources in consultation with the Country and Regional Data Group, analysed pooled data, and prepared results. B.Z. and M.E. wrote the first draft of the report with input from other members of Pooled Analysis and Writing Group. Members of Country and Regional Data Group commented on draft report.

## **Competing financial interests**

The authors declare no competing financial interests.





- 297 1. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL,  
 298 Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR,  
 299 Chalmers J, Ramirez AJ, Bakris GL, Wang J, et al. Clinical practice guidelines for the management of  
 300 hypertension in the community: a statement by the American Society of Hypertension and the  
 301 International Society of Hypertension. *J Clin Hypertens (Greenwich)*. 2014;16(1):14-26.
- 302 2. Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, Damasceno A, Delles C,  
 303 Gimenez-Roqueplo AP, Hering D, Lopez-Jaramillo P, Martinez F, Perkovic V, Rietzschel ER, Schillaci G,  
 304 Schutte AE, Scuteri A, Sharman JE, Wachtell K, Wang JG. A call to action and a lifecourse strategy to  
 305 address the global burden of raised blood pressure on current and future generations: the Lancet  
 306 Commission on hypertension. *Lancet*. 2016;388(10060):2665-712.
- 307 3. Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo J, Jones D, Materson B, Oparil S,  
 308 Wright J, Roccella E, National Heart L, Blood Institute Joint National Committee on Prevention DE,  
 309 Treatment of High Blood P, National High Blood Pressure Education Program Coordinating C. The  
 310 seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment  
 311 of high blood pressure: the JNC 7 report. *JAMA*. 2003;289(19):2560-72.
- 312 4. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a  
 313 pooled analysis of 1479 population-based measurement studies with 19.1 million participants.  
 314 *Lancet*. 2017;389(10064):37-55.
- 315 5. World Health Organization. Global action plan for the prevention and control of  
 316 noncommunicable diseases 2013-2020 World Health Organization, Geneva, Switzerland. 2013.  
 317 Available from: [http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf?ua=1).
- 318 6. Victora CG, Adair L, Fall C, Hallal PC, Martorell R, Richter L, Sachdev HS, Maternal, Child  
 319 Undernutrition Study G. Maternal and child undernutrition: consequences for adult health and  
 320 human capital. *Lancet*. 2008;371(9609):340-57.
- 321 7. Sacks FM, Campos H. Dietary therapy in hypertension. *N Engl J Med*. 2010;362(22):2102-12.
- 322 8. IOM (Institute of Medicine). A Population-Based Policy and Systems Change Approach to  
 323 Prevent and Control Hypertension. Washington, DC: The National Academies Press; 2010.
- 324 9. He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure:  
 325 Cochrane systematic review and meta-analysis of randomised trials. *BMJ*. 2013;346:f1325.
- 326 10. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased  
 327 potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses.  
 328 *BMJ*. 2013;346:f1378.
- 329 11. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction  
 330 in alcohol consumption on blood pressure: a systematic review and meta-analysis. *The Lancet Public*  
 331 *Health*. 2017;2(2):e108-e20.
- 332 12. Virdis A, Giannarelli C, Neves MF, Taddei S, Ghiadoni L. Cigarette smoking and hypertension.  
 333 *Curr Pharm Des*. 2010;16(23):2518-25.
- 334 13. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and  
 335 meta-analysis. *J Am Heart Assoc*. 2013;2(1):e004473.
- 336 14. Cai Y, Zhang B, Ke W, Feng B, Lin H, Xiao J, Zeng W, Li X, Tao J, Yang Z, Ma W, Liu T.  
 337 Associations of Short-Term and Long-Term Exposure to Ambient Air Pollutants With Hypertension: A  
 338 Systematic Review and Meta-Analysis. *Hypertension*. 2016;68(1):62-70.
- 339 15. Navas-Acien A, Schwartz BS, Rothenberg SJ, Hu H, Silbergeld EK, Guallar E. Bone lead levels  
 340 and blood pressure endpoints: a meta-analysis. *Epidemiology*. 2008;19(3):496-504.
- 341 16. Munzel T, Gori T, Babisch W, Basner M. Cardiovascular effects of environmental noise  
 342 exposure. *Eur Heart J*. 2014;35(13):829-36.
- 343 17. Gasperin D, Netuveli G, Dias-da-Costa JS, Pattussi MP. Effect of psychological stress on blood  
 344 pressure increase: a meta-analysis of cohort studies. *Cad Saude Publica*. 2009;25(4):715-26.

18. Rose G, Day S. The population mean predicts the number of deviant individuals. *BMJ*. 1990;301(6759):1031-4.
19. Laaser U, Breckenkamp J, Ullrich A, Hoffmann B. Can a decline in the population means of cardiovascular risk factors reduce the number of people at risk? *Journal of epidemiology and community health*. 2001;55(3):179-84.
20. Tunstall-Pedoe H, Connaghan J, Woodward M, Tolonen H, Kuulasmaa K. Pattern of declining blood pressure across replicate population surveys of the WHO MONICA project, mid-1980s to mid-1990s, and the role of medication. *BMJ*. 2006;332(7542):629-35.
21. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. *Hypertension*. 1995;26(1):60-9.
22. Goff DC, Howard G, Russell GB, Labarthe DR. Birth cohort evidence of population influences on blood pressure in the United States, 1887-1994. *Ann Epidemiol*. 2001;11(4):271-9.
23. Goff DC, Jr., Gillespie C, Howard G, Labarthe DR. Is the obesity epidemic reversing favorable trends in blood pressure? Evidence from cohorts born between 1890 and 1990 in the United States. *Annals of Epidemiology*. 2012;22(8):554-61.
24. Kastarinen MJ, Nissinen AM, Vartiainen EA, Jousilahti PJ, Korhonen HJ, Puska PM, Tuomilehto. Blood pressure levels and obesity trends in hypertensive and normotensive Finnish population from 1982 to 1997. *J Hypertens*. 2000;18(3):255-62.
25. Ulmer H, Kelleher CC, Fitz-Simon N, Diem G, Concin H. Secular trends in cardiovascular risk factors: an age-period cohort analysis of 6 98 954 health examinations in 1 81 350 Austrian men and women. *Journal of Internal Medicine*. 2007;261(6):566-76.
26. Long GH, Simmons RK, Norberg M, Wennberg P, Lindahl B, Rolandsson O, Griffin SJ, Weinehall L. Temporal Shifts in Cardiovascular Risk Factor Distribution. *American Journal of Preventive Medicine*. 2014;46(2):112-21.
27. Hopstock LA, Bonaa KH, Eggen AE, Grimsgaard S, Jacobsen BK, Lochen ML, Mathiesen EB, Njolstad I, Wilsgaard T. Longitudinal and Secular Trends in Blood Pressure Among Women and Men in Birth Cohorts Born Between 1905 and 1977: The Tromso Study 1979 to 2008. *Hypertension*. 2015;66(3):496-501.
28. Holmen J, Holmen TL, Tverdal A, Holmen OL, Sund ER, Midthjell K. Blood pressure changes during 22-year of follow-up in large general population - the HUNT Study, Norway. *BMC cardiovascular disorders*. 2016;16:94.
29. NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *Lancet*. 2016;387(10026):1377-96.
30. Du S, Batis C, Wang H, Zhang B, Zhang J, Popkin BM. Understanding the patterns and trends of sodium intake, potassium intake, and sodium to potassium ratio and their effect on hypertension in China. *Am J Clin Nutr*. 2014;99(2):334-43.
31. He FJ, Pombo-Rodrigues S, Macgregor GA. Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality. *BMJ Open*. 2014;4(4):e004549.
32. Ikeda N, Gakidou E, Hasegawa T, Murray CJ. Understanding the decline of mean systolic blood pressure in Japan: an analysis of pooled data from the National Nutrition Survey, 1986-2002. *Bull World Health Organ*. 2008;86(12):978-88.
33. Laatikainen T, Pietinen P, Valsta L, Sundvall J, Reinivuo H, Tuomilehto J. Sodium in the Finnish diet: 20-year trends in urinary sodium excretion among the adult population. *Eur J Clin Nutr*. 2006;60(8):965-70.
34. Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, Engell RE, Lim SS, Danaei G, Mozaffarian D, Global Burden of Diseases N, Chronic Diseases Expert G. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. *BMJ Open*. 2013;3(12):e003733.

35. Bernstein AM, Willett WC. Trends in 24-h urinary sodium excretion in the United States, 1957-2003: a systematic review. *Am J Clin Nutr.* 2010;92(5):1172-80.
36. Lee HS, Duffey KJ, Popkin BM. Sodium and potassium intake patterns and trends in South Korea. *J Hum Hypertens.* 2013;27(5):298-303.
37. Johnson C, Praveen D, Pope A, Raj TS, Pillai RN, Land MA, Neal B. Mean population salt consumption in India: a systematic review. *J Hypertens.* 2017;35(1):3-9.
38. Sarno F, Claro RM, Levy RB, Bandoni DH, Monteiro CA. [Estimated sodium intake for the Brazilian population, 2008-2009]. *Rev Saude Publica.* 2013;47(3):571-8.
39. Bilano V, Gilmour S, Moffiet T, d'Espaignet ET, Stevens GA, Commar A, Tuyl F, Hudson I, Shibuya K. Global trends and projections for tobacco use, 1990-2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control. *Lancet.* 2015;385(9972):966-76.
40. Micha R, Khatibzadeh S, Shi P, Andrews KG, Engell RE, Mozaffarian D, Global Burden of Diseases N, Chronic Diseases Expert G. Global, regional and national consumption of major food groups in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys worldwide. *BMJ Open.* 2015;5(9):e008705.
41. Lewington S, Li L, Sherliker P, Guo Y, Millwood I, Bian Z, Whitlock G, Yang L, Collins R, Chen J, Wu X, Wang S, Hu Y, Jiang L, Yang L, Lacey B, Peto R, Chen Z, China Kadoorie Biobank study c. Seasonal variation in blood pressure and its relationship with outdoor temperature in 10 diverse regions of China: the China Kadoorie Biobank. *J Hypertens.* 2012;30(7):1383-91.
42. Saeki K, Obayashi K, Iwamoto J, Tanaka Y, Tanaka N, Takata S, Kubo H, Okamoto N, Tomioka K, Nezu S, Kurumatani N. Influence of room heating on ambulatory blood pressure in winter: a randomised controlled study. *Journal of epidemiology and community health.* 2013;67(6):484-90.
43. Wang Q, Li C, Guo Y, Barnett AG, Tong S, Phung D, Chu C, Dear K, Wang X, Huang C. Environmental ambient temperature and blood pressure in adults: A systematic review and meta-analysis. *Sci Total Environ.* 2017;575:276-86.
44. NCD Risk Factor Collaboration. A century of trends in adult human height. *eLife.* 2016;5:e13410.
45. McCarron P, Smith GD, Okasha M. Secular changes in blood pressure in childhood, adolescence and young adulthood: systematic review of trends from 1948 to 1998. *J Hum Hypertens.* 2002;16(10):677-89.
46. Dong B, Wang Z, Song Y, Wang HJ, Ma J. Understanding trends in blood pressure and their associations with body mass index in Chinese children, from 1985 to 2010: a cross-sectional observational study. *BMJ Open.* 2015;5(9):e009050.
47. Khang YH, Lynch JW. Exploring determinants of secular decreases in childhood blood pressure and hypertension. *Circulation.* 2011;124(4):397-405.
48. Chiolerio A, Paradis G, Madeleine G, Hanley JA, Paccaud F, Bovet P. Discordant secular trends in elevated blood pressure and obesity in children and adolescents in a rapidly developing country. *Circulation.* 2009;119(4):558-65.
49. Xi B, Zhang T, Zhang M, Liu F, Zong X, Zhao M, Wang Y. Trends in Elevated Blood Pressure Among US Children and Adolescents: 1999-2012. *Am J Hypertens.* 2016;29(2):217-25.
50. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. *JAMA.* 1977;237(3):255-61.
51. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J.* 2013;34(28):2159-219.
52. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. *JAMA.* 2010;303(20):2043-50.

53. Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008-11. *J Hum Hypertens*. 2015;29(4):247-53.
54. Reklaitiene R, Tamosiunas A, Virviciute D, Baceviciene M, Luksiene D. Trends in prevalence, awareness, treatment, and control of hypertension, and the risk of mortality among middle-aged Lithuanian urban population in 1983-2009. *BMC cardiovascular disorders*. 2012;12:68.
55. McAlister FA, Wilkins K, Joffres M, Leenen FH, Fodor G, Gee M, Tremblay MS, Walker R, Johansen H, Campbell N. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. *CMAJ*. 2011;183(9):1007-13.
56. Cifkova R, Skodova Z, Bruthans J, Adamkova V, Jozifova M, Galovcova M, Wohlfahrt P, Krajcoviechova A, Poledne R, Stavek P, Lanska V. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. *Czech MONICA and Czech post-MONICA. Atherosclerosis*. 2010;211(2):676-81.
57. Kastarinen M, Antikainen R, Peltonen M, Laatikainen T, Barengo NC, Jula A, Salomaa V, Jousilahti P, Nissinen A, Vartiainen E, Tuomilehto J. Prevalence, awareness and treatment of hypertension in Finland during 1982-2007. *J Hypertens*. 2009;27(8):1552-9.
58. Torma E, Carlberg B, Eriksson M, Jansson JH, Eliasson M. Long term trends in control of hypertension in the Northern Sweden MONICA study 1986-2009. *BMC Public Health*. 2015;15:957.
59. Sans S, Paluzie G, Balana L, Puig T, Balaguer-Vintro I. [Trends in prevalence, awareness, treatment and control of arterial hypertension between 1986 and 1996: the MONICA-Catalonia study]. *Med Clin (Barc)*. 2001;117(7):246-53.
60. Fasce E, Campos I, Ibanez P, Flores M, Zarate H, Roman O, Fasce F. Trends in prevalence, awareness, treatment and control of hypertension in urban communities in Chile. *J Hypertens*. 2007;25(9):1807-11.
61. Sengul S, Akpolat T, Erdem Y, Derici U, Arici M, Sindel S, Karatan O, Turgan C, Hasanoglu E, Caglar S, Erturk S, Turkish Society of H, Renal D. Changes in hypertension prevalence, awareness, treatment, and control rates in Turkey from 2003 to 2012. *J Hypertens*. 2016;34(6):1208-17.
62. Hou Z, Meng Q, Zhang Y. Hypertension Prevalence, Awareness, Treatment, and Control Following China's Healthcare Reform. *Am J Hypertens*. 2016;29(4):428-31.
63. Dorobantu M, Darabont R, Ghiorghe S, Arsenescu-Georgescu C, Macarie C, Mitu F, Lighezan D, Musetescu R, Pop C, Ardeleanu E, Craiu E, Tautu OF. Hypertension prevalence and control in Romania at a seven-year interval. Comparison of SEPHAR I and II surveys. *J Hypertens*. 2014;32(1):39-47.
64. Xi B, Liang Y, Reilly KH, Wang Q, Hu Y, Tang W. Trends in prevalence, awareness, treatment, and control of hypertension among Chinese adults 1991-2009. *Int J Cardiol*. 2012;158(2):326-9.
65. Pilav A, Doder V, Brankovic S. Awareness, Treatment, and control of Hypertension among Adult Population in the Federation of Bosnia and Herzegovina over the Past Decade. *J Public Health Res*. 2014;3(3):323.
66. NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet*. 2016;387(10027):1513-30.
67. McFadden D. Conditional Logit Analysis of Qualitative Choice Behavior. In: Zarembka P, editor. *Frontiers in econometrics*: Academic Press; 1974. p. 105-42.






Interaction of the two = Total change - ( Contribution of the change in mean blood pressure + Contribution of the change in the association )

**Figure 1:** Schematic diagram for the contributions of change in mean blood pressure and in shape of the blood pressure distribution to the change in prevalence of raised blood pressure.


Each S-shaped curve shows what the prevalence of raised blood pressure would be at different levels of population mean for a specific shape of population distribution. A change in mean without a change in the shape of the distribution (Panel A) would move prevalence along a curve (blue point in Panel D). A change in the shape of the distribution without a change in mean (Panel B) would vertically move prevalence from one curve to another (purple point in Panel D). The combination (Panel C) would move prevalence from one curve to another, as well as along the curve (orange point in Panel D)

The figure shows the contributions when raised blood pressure is defined based on one blood pressure (either SBP or DBP). The same concept applies when raised blood pressure is defined based on both SBP and DBP.


Prevalence of raised blood pressure (%)



Mean systolic blood pressure (mmHg)




Mean diastolic blood pressure (mmHg)




— 2005–2016    --- 1985–1994    decrease    increase


Prevalence of raised blood pressure (%)



Mean systolic blood pressure (mmHg)



Mean diastolic blood pressure (mmHg)



— 2005–2016    - - - 1985–1994    decrease    increase

503 **Figure 2:** Changes in prevalence of raised blood pressure, mean SBP and mean DBP from  
504 1985-1994 to 2005-2016 by region for men and women, by age group.

20–49 years

50–79 years

South Asia

Central Asia, Middle East and north Africa

Latin America and the Caribbean

Oceania

East and southeast Asia

Sub-Saharan Africa

High-income western

Central and eastern Europe

High-income Asia Pacific

South Asia

Central Asia, Middle East and north Africa

Latin America and the Caribbean

Oceania

East and southeast Asia

Sub-Saharan Africa

High-income western

Central and eastern Europe

High-income Asia Pacific

Women

Men


-4 -2 0 2 4

-4 -2 0 2 4

Percentage point difference from the world average prevalence

505 **Figure 3:** Regional differences in prevalence of raised blood pressure among men and  
506 women aged 20-49 years and 50-79 years in 2005-2016 if every region had the same mean  
507 SBP and DBP, equal to the global age-sex-specific mean in 2010.

508





509 **Figure 4:** Contributions of change in mean blood pressure, change in prevalence-mean  
510 association, and the interaction of the two, to change in prevalence of raised blood pressure  
511 since 1985-1994 by region for men and women aged 20-49 years and 50-79 years.

512 **NCD Risk Factor Collaboration (NCD-RisC)**

513 Pooled Analysis and Writing

514 Bin Zhou (Imperial College London, UK); James Bentham (University of Kent, UK; Imperial  
515 College London, UK); Mariachiara Di Cesare (Middlesex University, UK); Honor Bixby  
516 (Imperial College London, UK); Goodarz Danaei (Harvard TH Chan School of Public Health,  
517 USA); Kaveh Hajifathalian (Cleveland Clinic, USA); Cristina Taddei (Imperial College  
518 London, UK); Rodrigo M Carrillo-Larco (Universidad Peruana Cayetano Heredia, Peru);  
519 Shirin Djalalinia (Tehran University of Medical Sciences, Iran); Shahab Khatibzadeh  
520 (Brandeis University, USA); Charles Lugero (Mulago Hospital, Uganda); Niloofar Peykari  
521 (Tehran University of Medical Sciences, Iran); Wan Zhu Zhang (Uganda Heart Institute,  
522 Uganda); Ver Bilano (Imperial College London, UK); Gretchen A Stevens (World Health  
523 Organization, Switzerland); Melanie J Cowan (World Health Organization, Switzerland);  
524 Leanne M Riley (World Health Organization, Switzerland); Prof Zhengming Chen  
525 (University of Oxford, UK); Prof Ian R Hambleton (The University of the West Indies,  
526 Barbados); Prof Rod T Jackson (University of Auckland, New Zealand); Prof Andre Pascal  
527 Kengne (South African Medical Research Council, South Africa); Prof Young-Ho Khang  
528 (Seoul National University, Republic of Korea); Prof Avula Laxmaiah (National Institute of  
529 Nutrition, India); Jing Liu (Capital Medical University Beijing An Zhen Hospital, China);  
530 Prof Reza Malekzadeh (Tehran University of Medical Sciences, Iran); Hannelore K  
531 Neuhauser (Robert Koch Institute, Germany); Maroje Sorić (University of Zagreb, Croatia);  
532 Gregor Starc (University of Ljubljana, Slovenia); Prof Johan Sundström (Uppsala University,  
533 Sweden); Prof Mark Woodward (University of New South Wales, Australia; University of  
534 Oxford, UK); Prof Majid Ezzati (Imperial College London, UK)

535

536

537 Country and Regional Data (\* equal contribution; listed alphabetically)

538 Leandra Abarca-Gómez (Caja Costarricense de Seguro Social, Costa Rica)\*; Ziad A Abdeen

539 (Al-Quds University, Palestine)\*; Niveen M Abu-Rmeileh (Birzeit University, Palestine)\*;

540 Benjamin Acosta-Cazares (Instituto Mexicano del Seguro Social, Mexico)\*; Robert Adams

541 (The University of Adelaide, Australia)\*; Wichai Aekplakorn (Mahidol University,

542 Thailand)\*; Kaosar Afsana (BRAC, Bangladesh)\*; Carlos A Aguilar-Salinas (Instituto

543 Nacional de Ciencias Médicas y Nutricion, Mexico)\*; Charles Agyemang (University of

544 Amsterdam, The Netherlands)\*; Alireza Ahmadvand (Non-Communicable Diseases

545 Research Center, Iran)\*; Wolfgang Ahrens (Leibniz Institute for Prevention Research and

546 Epidemiology - BIPS, Germany)\*; Kamel Ajlouni (National Center for Diabetes and

547 Endocrinology, Jordan)\*; Nazgul Akhtaeva (Kazakh National Medical University,

548 Kazakhstan)\*; Rajaa Al-Raddadi (Ministry of Health, Saudi Arabia)\*; Mohamed M Ali

549 (World Health Organization, Switzerland)\*; Osman Ali (Universiti Malaysia Sabah,

550 Malaysia)\*; Ala'a Alkerwi (Luxembourg Institute of Health, Luxembourg)\*; Eman Aly

551 (World Health Organization Regional Office for the Eastern Mediterranean, Egypt)\*; Deepak

552 N Amarapurkar (Bombay Hospital and Medical Research Centre, India)\*; Philippe Amouyel

553 (Lille University and Hospital, France)\*; Antoinette Amuzu (London School of Hygiene &

554 Tropical Medicine, UK)\*; Lars Bo Andersen (Western Norwegian University of Applied

555 Sciences, Norway)\*; Sigmund A Anderssen (Norwegian School of Sport Sciences, Norway)\*;

556 Lars H Ängquist (Bispebjerg and Frederiksberg Hospitals, Denmark)\*; Ranjit Mohan Anjana

557 (Madras Diabetes Research Foundation, India)\*; Daniel Ansong (Komfo Anokye Teaching

558 Hospital, Ghana)\*; Hajer Aounallah-Skhiri (National Institute of Public Health, Tunisia)\*;

559 Joana Araújo (Universidade do Porto, Portugal)\*; Inger Ariansen (Norwegian Institute of

560 Public Health, Norway)\*; Tahir Aris (Ministry of Health Malaysia, Malaysia)\*; Nimmathota

561 Arlappa (Indian Council of Medical Research, India)\*; Dominique Arveiler (Strasbourg

562 University and Hospital, France)\*; Krishna K Aryal (Nepal Health Research Council,  
 563 Nepal)\*; Thor Aspelund (Icelandic Heart Association, Iceland)\*; Felix K Assah (University  
 564 of Yaoundé 1, Cameroon)\*; Maria Cecília F Assunção (Federal University of Pelotas,  
 565 Brazil)\*; Mária Avdicová (Regional Authority of Public Health, Banska Bystrica, Slovakia)\*;  
 566 Ana Azevedo (University of Porto Medical School, Portugal)\*; Fereidoun Azizi (Shahid  
 567 Beheshti University of Medical Sciences, Iran)\*; Bontha V Babu (Indian Council of Medical  
 568 Research, India)\*; Suhad Bahijri (King Abdulaziz University, Saudi Arabia)\*; Nagalla  
 569 Balakrishna (Indian Council of Medical Research, India)\*; Mohamed Bamoshmoosh  
 570 (University of Science and Technology, Yemen)\*; Piotr Bandosz (Medical University of  
 571 Gdansk, Poland)\*; José R Banegas (Universidad Autónoma de Madrid, Spain)\*; Carlo M  
 572 Barbagallo (University of Palermo, Italy)\*; Alberto Barceló (Pan American Health  
 573 Organization, USA)\*; Amina Barkat (Université Mohammed V de Rabat, Morocco)\*;  
 574 Aluisio JD Barros (Federal University of Pelotas, Brazil)\*; Mauro V Barros (University of  
 575 Pernambuco, Brazil)\*; Iqbal Bata (Dalhousie University, Canada)\*; Anwar M Batieha  
 576 (Jordan University of Science and Technology, Jordan)\*; Assembekov Batyrbek (Kazakh  
 577 National Medical University, Kazakhstan)\*; Louise A Baur (University of Sydney,  
 578 Australia)\*; Robert Beaglehole (University of Auckland, New Zealand)\*; Habiba Ben  
 579 Romdhane (University Tunis El Manar, Tunisia)\*; Mikhail Benet (University Medical  
 580 Science, Cuba)\*; Lowell S Benson (University of Utah School of Medicine, USA)\*; Antonio  
 581 Bernabe-Ortiz (Universidad Peruana Cayetano Heredia, Peru)\*; Gailute Bernotiene  
 582 (Lithuanian University of Health Sciences, Lithuania)\*; Heloisa Bettiol (University of São  
 583 Paulo, Brazil)\*; Aroor Bhagyalaxmi (B. J. Medical College, India)\*; Sumit Bharadwaj  
 584 (Chirayu Medical College, India)\*; Santosh K Bhargava (SL Jain Hospital, India)\*; Yufang  
 585 Bi (Shanghai Jiao-Tong University School of Medicine, China)\*; Mukharram Bikbov (Ufa  
 586 Eye Research Institute, Russia)\*; Bihungum Bista (Nepal Health Research Council, Nepal)\*;

587 Peter Bjerregaard (University of Southern Denmark, Denmark; University of Greenland,  
 588 Greenland)\*; Espen Bjertness (University of Oslo, Norway)\*; Marius B Bjertness (University  
 589 of Oslo, Norway)\*; Cecilia Björkelund (University of Gothenburg, Sweden)\*; Anneke  
 590 Blokstra (National Institute for Public Health and the Environment, The Netherlands)\*;  
 591 Simona Bo (University of Turin, Italy)\*; Martin Bobak (University College London, UK)\*;  
 592 Heiner Boeing (German Institute of Human Nutrition, Germany)\*; Jose G Boggia  
 593 (Universidad de la República, Uruguay)\*; Carlos P Boissonnet (CEMIC, Argentina)\*;  
 594 Vanina Bongard (Toulouse University School of Medicine, France)\*; Rossana Borchini  
 595 (University Hospital of Varese, Italy)\*; Pascal Bovet (Ministry of Health, Seychelles;  
 596 University of Lausanne, Switzerland)\*; Lutgart Braeckman (Ghent University, Belgium)\*;  
 597 Imperia Brajkovich (Universidad Central de Venezuela, Venezuela)\*; Francesco Branca  
 598 (World Health Organization, Switzerland)\*; Juergen Breckenkamp (Bielefeld University,  
 599 Germany)\*; Hermann Brenner (German Cancer Research Center, Germany)\*; Lizzy M  
 600 Brewster (University of Amsterdam, The Netherlands)\*; Graziella Bruno (University of  
 601 Turin, Italy)\*; H.B(as) Bueno-de-Mesquita (National Institute for Public Health and the  
 602 Environment, The Netherlands)\*; Anna Bugge (University of Southern Denmark, Denmark)\*;  
 603 Con Burns (Cork Institute of Technology, Ireland)\*; Michael Burszty (Hadassah-Hebrew  
 604 University Medical Center, Israel)\*; Antonio Cabrera de León (Universidad de La Laguna,  
 605 Spain)\*; Joseph Cacciottolo (University of Malta, Malta)\*; Hui Cai (Vanderbilt University,  
 606 USA)\*; Christine Cameron (Canadian Fitness and Lifestyle Research Institute, Canada)\*;  
 607 Günay Can (Istanbul University, Turkey)\*; Ana Paula C Cândido (Universidade Federal de  
 608 Juiz de Fora, Brazil)\*; Vincenzo Capuano (Cardiologia di Mercato S. Severino, Italy)\*;  
 609 Viviane C Cardoso (University of São Paulo, Brazil)\*; Axel C Carlsson (Karolinska Institutet,  
 610 Sweden)\*; Maria J Carvalho (University of Porto, Portugal)\*; Felipe F Casanueva (Santiago  
 611 de Compostela University, Spain)\*; Juan-Pablo Casas (University College London, UK)\*;

612 Carmelo A Caserta (Associazione Calabrese di Epatologia, Italy)\*; Snehalatha Chamukuttan  
 613 (India Diabetes Research Foundation, India)\*; Angelique W Chan (Duke-NUS Medical  
 614 School, Singapore)\*; Queenie Chan (Imperial College London, UK)\*; Himanshu K  
 615 Chaturvedi (National Institute of Medical Statistics, India)\*; Nishi Chaturvedi (University  
 616 College London, UK)\*; Chien-Jen Chen (Academia Sinica, Taiwan)\*; Fangfang Chen  
 617 (Capital Institute of Pediatrics, China)\*; Huashuai Chen (Duke University, USA)\*; Shuohua  
 618 Chen (Kailuan General Hospital, China)\*; Zhengming Chen (University of Oxford, UK)\*;  
 619 Ching-Yu Cheng (Duke-NUS Medical School, Singapore)\*; Imane Cherkaoui Dekkaki  
 620 (Université Mohammed V de Rabat, Morocco)\*; Angela Chetrit (The Gertner Institute for  
 621 Epidemiology and Health Policy Research, Israel)\*; Arnaud Chiolerio (University of Bern,  
 622 Switzerland)\*; Shu-Ti Chiou (Ministry of Health and Welfare, Taiwan)\*; Adela Chirita-  
 623 Emandi (Victor Babes University of Medicine and Pharmacy, Romania)\*; María-Dolores  
 624 Chirlaque (Murcia Regional Health Council, Spain)\*; Belong Cho (Seoul National University  
 625 College of Medicine, South Korea)\*; Yumi Cho (Korea Centers for Disease Control and  
 626 Prevention, South Korea)\*; Jerzy Chudek (Medical University of Silesia, Poland)\*; Renata  
 627 Cifkova (Charles University in Prague, Czech Republic)\*; Eliza Cinteza (Carol Davila  
 628 University of Medicine and Pharmacy, Romania)\*; Frank Claessens (Katholieke Universiteit  
 629 Leuven, Belgium)\*; Els Clays (Ghent University, Belgium)\*; Hans Concina (Agency for  
 630 Preventive and Social Medicine, Austria)\*; Cyrus Cooper (University of Southampton, UK)\*;  
 631 Rachel Cooper (University College London, UK)\*; Tara C Coppinger (Cork Institute of  
 632 Technology, Ireland)\*; Simona Costanzo (IRCCS Istituto Neurologico Mediterraneo  
 633 Neuromed, Italy)\*; Dominique Cottel (Institut Pasteur de Lille, France)\*; Chris Cowell  
 634 (University of Sydney, Australia)\*; Cora L Craig (Canadian Fitness and Lifestyle Research  
 635 Institute, Canada)\*; Ana B Crujeiras (CIBEROBN, Spain)\*; Juan J Cruz (Universidad  
 636 Autónoma de Madrid, Spain)\*; Graziella D'Arrigo (National Council of Research, Italy)\*;



662 University of Health Sciences, Lithuania)\*; Aleksandar Džakula (University of Zagreb,  
 663 Croatia)\*; Vilnis Dzerve (University of Latvia, Latvia)\*; Elzbieta Dziankowska-Zaborszczyk  
 664 (Medical University of Lodz, Poland)\*; Robert Eggertsen (University of Gothenburg,  
 665 Sweden)\*; Ulf Ekelund (Norwegian School of Sport Sciences, Norway)\*; Jalila El Ati  
 666 (National Institute of Nutrition and Food Technology, Tunisia)\*; Paul Elliott (Imperial  
 667 College London, UK)\*; Roberto Elosua (Institut Hospital del Mar d'Investigacions Mèdiques,  
 668 Spain)\*; Rajiv T Erasmus (University of Stellenbosch, South Africa)\*; Cihangir Erem  
 669 (Karadeniz Technical University, Turkey)\*; Louise Eriksen (University of Southern Denmark,  
 670 Denmark)\*; Jorge Escobedo-de la Peña (Instituto Mexicano del Seguro Social, Mexico)\*;  
 671 Alun Evans (The Queen's University of Belfast, UK)\*; David Faeh (University of Zurich,  
 672 Switzerland)\*; Caroline H Fall (University of Southampton, UK)\*; Farshad Farzadfar  
 673 (Tehran University of Medical Sciences, Iran)\*; Francisco J Felix-Redondo (Centro de Salud  
 674 Villanueva Norte, Spain)\*; Trevor S Ferguson (The University of the West Indies, Jamaica)\*;  
 675 Daniel Fernández-Bergés (Hospital Don Benito-Villanueva de la Serena, Spain)\*; Daniel  
 676 Ferrante (Ministry of Health, Argentina)\*; Marika Ferrari (Council for Agricultural Research  
 677 and Economics, Italy)\*; Catterina Ferreccio (Pontificia Universidad Católica de Chile,  
 678 Chile)\*; Jean Ferrieres (Toulouse University School of Medicine, France)\*; Joseph D Finn  
 679 (University of Manchester, UK)\*; Krista Fischer (University of Tartu, Estonia)\*; Bernhard  
 680 Föger (Agency for Preventive and Social Medicine, Austria)\*; Leng Huat Foo (Universiti  
 681 Sains Malaysia, Malaysia)\*; Ann-Sofie Forslund (Umeå University, Sweden)\*; Maria  
 682 Forsner (Dalarna University, Sweden)\*; Heba M Fouad (World Health Organization  
 683 Regional Office for the Eastern Mediterranean, Egypt)\*; Damian K Francis (The University  
 684 of the West Indies, Jamaica)\*; Maria do Carmo Franco (Federal University of São Paulo,  
 685 Brazil)\*; Oscar H Franco (Erasmus Medical Center Rotterdam, The Netherlands)\*;  
 686 Guillermo Frontera (Hospital Universitario Son Espases, Spain)\*; Flavio D Fuchs (Hospital



687 de Clinicas de Porto Alegre, Brazil)\*; Sandra C Fuchs (Universidade Federal do Rio Grande  
 688 do Sul, Brazil)\*; Yuki Fujita (Kindai University, Japan)\*; Takuro Furusawa (Kyoto  
 689 University, Japan)\*; Zbigniew Gaciong (Medical University of Warsaw, Poland)\*; Fabio  
 690 Galvano (University of Catania, Italy)\*; Manoli Garcia-de-la-Hera (CIBER en Epidemiología  
 691 y Salud Pública, Spain)\*; Dickman Gareta (University of KwaZulu-Natal, South Africa)\*;  
 692 Sarah P Garnett (University of Sydney, Australia)\*; Jean-Michel Gaspoz (Geneva University  
 693 Hospitals, Switzerland)\*; Magda Gasull (CIBER en Epidemiología y Salud Pública, Spain)\*;  
 694 Louise Gates (Australian Bureau of Statistics, Australia)\*; Johanna M Geleijnse  
 695 (Wageningen University, The Netherlands)\*; Anoosheh Ghasemian (Non-Communicable  
 696 Diseases Research Center, Iran)\*; Anup Ghimire (B P Koirala Institute of Health Sciences,  
 697 Nepal)\*; Simona Giampaoli (Istituto Superiore di Sanità, Italy)\*; Francesco Gianfagna  
 698 (University of Insubria, Italy)\*; Jonathan Giovannelli (Lille University Hospital, France)\*;  
 699 Rebecca A Goldsmith (Ministry of Health, Israel)\*; Helen Gonçalves (Federal University of  
 700 Pelotas, Brazil)\*; Juan P González-Rivas (The Andes Clinic of Cardio-Metabolic Studies,  
 701 Venezuela)\*; Marcela Gonzalez Gross (Universidad Politécnica de Madrid, Spain)\*; Mariano  
 702 Bonet Gorbea (National Institute of Hygiene, Epidemiology and Microbiology, Cuba)\*;  
 703 Frederic Gottrand (Université de Lille 2, France)\*; Sidsel Graff-Iversen (Norwegian Institute  
 704 of Public Health, Norway)\*; Dušan Grafnetter (Institute for Clinical and Experimental  
 705 Medicine, Czech Republic)\*; Aneta Grajda (The Children's Memorial Health Institute,  
 706 Poland)\*; Ronald D Gregor (Dalhousie University, Canada)\*; Tomasz Grodzicki  
 707 (Jagiellonian University Medical College, Poland)\*; Anders Grøntved (University of  
 708 Southern Denmark, Denmark)\*; Giuseppe Grosso (Azienda Ospedaliera Universitaria  
 709 Policlinico Vittorio Emanuele, Italy)\*; Gabriella Gruden (University of Turin, Italy)\*; Vera  
 710 Grujic (University of Novi Sad, Serbia)\*; Dongfeng Gu (National Center of Cardiovascular  
 711 Diseases, China)\*; Ong Peng Guan (Singapore Eye Research Institute, Singapore)\*; Elias F

712 Gudmundsson (Icelandic Heart Association, Iceland)\*; Vilmundur Gudnason (University of  
 713 Iceland, Iceland)\*; Ramiro Guerrero (Universidad Icesi, Colombia)\*; Idris Guessous (Geneva  
 714 University Hospitals, Switzerland)\*; Andre L Guimaraes (State University of Montes Claros,  
 715 Brazil)\*; Martin C Gulliford (King's College London, UK)\*; Johanna Gunnlaugsdottir  
 716 (Icelandic Heart Association, Iceland)\*; Marc Gunter (Imperial College London, UK)\*;  
 717 Prakash C Gupta (Healis-Sekhsaria Institute for Public Health, India)\*; Rajeev Gupta  
 718 (Eternal Heart Care Centre & Research Institute, India)\*; Oye Gureje (University of Ibadan,  
 719 Nigeria)\*; Beata Gurzkowska (The Children's Memorial Health Institute, Poland)\*; Laura  
 720 Gutierrez (Institute for Clinical Effectiveness and Health Policy, Argentina)\*; Felix  
 721 Gutzwiller (University of Zurich, Switzerland)\*; Farzad Hadaegh (Shahid Beheshti  
 722 University of Medical Sciences, Iran)\*; Khairil Azhar Haji Si-Ramlee (Ministry of Health,  
 723 Brunei)\*; Jytte Halkjær (Danish Cancer Society Research Centre, Denmark)\*; Ian R  
 724 Hambleton (The University of the West Indies, Barbados)\*; Rebecca Hardy (University  
 725 College London, UK)\*; Rachakulla Hari Kumar (Indian Council of Medical Research,  
 726 India)\*; Jun Hata (Kyushu University, Japan)\*; Alison J Hayes (University of Sydney,  
 727 Australia)\*; Jiang He (Tulane University, USA)\*; Marleen Elisabeth Hendriks (Academic  
 728 Medical Center of University of Amsterdam, The Netherlands)\*; Ana Henriques  
 729 (Universidade do Porto, Portugal)\*; Leticia Hernandez Cadena (National Institute of Public  
 730 Health, Mexico)\*; Sauli Herrala (Oulu University Hospital, Finland)\*; Ramin Heshmat  
 731 (Chronic Diseases Research Center, Iran)\*; Ilpo Tapani Hihtaniemi (Imperial College  
 732 London, UK)\*; Sai Yin Ho (University of Hong Kong, China)\*; Suzanne C Ho (The Chinese  
 733 University of Hong Kong, China)\*; Michael Hobbs (University of Western Australia,  
 734 Australia)\*; Albert Hofman (Erasmus Medical Center Rotterdam, The Netherlands)\*; Gonul  
 735 Horasan Dinc (Celal Bayar University, Turkey)\*; Andrea RVR Horimoto (Heart Institute,  
 736 Brazil)\*; Claudia M Hormiga (Fundación Oftalmológica de Santander, Colombia)\*;

737 Bernardo L Horta (Federal University of Pelotas, Brazil)\*; Leila Houti (University of Oran 1,  
 738 Algeria)\*; Christina Howitt (The University of the West Indies, Barbados)\*; Thein Thein  
 739 Htay (Independent Public Health Specialist, Myanmar)\*; Aung Soe Htet (Ministry of Health,  
 740 Myanmar)\*; Maung Maung Than Htike (Ministry of Health, Myanmar)\*; Yonghua Hu  
 741 (Peking University, China)\*; José María Huerta (CIBER en Epidemiología y Salud Pública,  
 742 Spain)\*; Martijn Huisman (Amsterdam Public Health Institute, The Netherlands)\*; Abdullatif  
 743 S Husseini (Birzeit University, Palestine)\*; Inge Huybrechts (International Agency for  
 744 Research on Cancer, France)\*; Nahla Hwalla (American University of Beirut, Lebanon)\*;  
 745 Licia Iacoviello (IRCCS Istituto Neurologico Mediterraneo Neuromed, Italy)\*; Anna G  
 746 Iannone (Cardiologia di Mercato S. Severino, Italy)\*; Mohsen M Ibrahim (Cairo University,  
 747 Egypt)\*; Nayu Ikeda (National Institute of Health and Nutrition, Japan)\*; M Arfan Ikram  
 748 (Erasmus Medical Center Rotterdam, The Netherlands)\*; Vilma E Irazola (Institute for  
 749 Clinical Effectiveness and Health Policy, Argentina)\*; Muhammad Islam (Aga Khan  
 750 University, Pakistan)\*; Aziz al-Safi Ismail (Universiti Sains Malaysia, Malaysia)\*; Vanja  
 751 Ivkovic (UHC Zagreb, Croatia)\*; Masanori Iwasaki (Niigata University, Japan)\*; Rod T  
 752 Jackson (University of Auckland, New Zealand)\*; Jeremy M Jacobs (Hadassah University  
 753 Medical Center, Israel)\*; Hashem Jaddou (Jordan University of Science and Technology,  
 754 Jordan)\*; Tazeen Jafar (Duke-NUS Medical School, Singapore)\*; Konrad Jamrozik  
 755 (University of Adelaide, Australia; deceased)\*; Imre Janszky (Norwegian University of  
 756 Science and Technology, Norway)\*; Grazyna Jasienska (Jagiellonian University Medical  
 757 College, Poland)\*; Ana Jelaković (UHC Zagreb, Croatia)\*; Bojan Jelaković (University of  
 758 Zagreb School of Medicine, Croatia)\*; Garry Jennings (Heart Foundation, Australia)\*; Chao  
 759 Qiang Jiang (Guangzhou 12th Hospital, China)\*; Michel Joffres (Simon Fraser University,  
 760 Canada)\*; Mattias Johansson (International Agency for Research on Cancer, France)\*; Jost B  
 761 Jonas (Ruprecht-Karls-University of Heidelberg, Germany)\*; Torben Jørgensen (Research

762 Centre for Prevention and Health, Denmark)\*; Pradeep Joshi (World Health Organization  
 763 Country Office, India)\*; Anne Juolevi (National Institute for Health and Welfare, Finland)\*;  
 764 Gregor Jurak (University of Ljubljana, Slovenia)\*; Vesna Jureša (University of Zagreb,  
 765 Croatia)\*; Rudolf Kaaks (German Cancer Research Center, Germany)\*; Anthony Kafatos  
 766 (University of Crete, Greece)\*; Ofra Kalter-Leibovici (The Gertner Institute for  
 767 Epidemiology and Health Policy Research, Israel)\*; Nor Azmi Kamaruddin (Universiti  
 768 Kebangsaan Malaysia, Malaysia)\*; Khem B Karki (Nepal Health Research Council, Nepal)\*;  
 769 Amir Kasaeian (Tehran University of Medical Sciences, Iran)\*; Norhayati Kassim (Ministry  
 770 of Health, Brunei)\*; Joanne Katz (Johns Hopkins Bloomberg School of Public Health,  
 771 USA)\*; Jussi Kauhanen (University of Eastern Finland, Finland)\*; Prabhdeep Kaur (National  
 772 Institute of Epidemiology, India)\*; Maryam Kavousi (Erasmus Medical Center Rotterdam,  
 773 The Netherlands)\*; Gyulli Kazakbaeva (Ufa Eye Research Institute, Russia)\*; Ulrich Keil  
 774 (University of Münster, Germany)\*; Lital Keinan Boker (Israel Center for Disease Control,  
 775 Israel)\*; Sirkka Keinänen-Kiukaanniemi (Oulu University Hospital, Finland)\*; Roya  
 776 Kelishadi (Isfahan University of Medical Sciences, Iran)\*; Han CG Kemper (VU University  
 777 Medical Center, The Netherlands)\*; Andre P Kengne (South African Medical Research  
 778 Council, South Africa)\*; Alina Kerimkulova (Kyrgyz State Medical Academy, Kyrgyzstan)\*;  
 779 Mathilde Kersting (Research Institute of Child Nutrition, Germany)\*; Timothy Key  
 780 (University of Oxford, UK)\*; Yousef Saleh Khader (Jordan University of Science and  
 781 Technology, Jordan)\*; Davood Khalili (Shahid Beheshti University of Medical Sciences,  
 782 Iran)\*; Young-Ho Khang (Seoul National University, South Korea)\*; Mohammad Khateeb  
 783 (National Center for Diabetes and Endocrinology, Jordan)\*; Kay-Tee Khaw (University of  
 784 Cambridge, UK)\*; Ursula Kiechl-Kohlendorfer (Medical University of Innsbruck, Austria)\*;  
 785 Stefan Kiechl (Medical University of Innsbruck, Austria)\*; Japhet Killewo (Muhimbili  
 786 University of Health and Allied Sciences, Tanzania)\*; Jeongseon Kim (National Cancer

787 Center, South Korea)\*; Magdalena Klimek, (Jagiellonian University Medical College,  
 788 Poland)\*; Jurate Klumbiene (Lithuanian University of Health Sciences, Lithuania)\*; Michael  
 789 Knoflach (Medical University of Innsbruck, Austria)\*; Elin Kolle (Norwegian School of  
 790 Sport Sciences, Norway)\*; Patrick Kolsteren (Institute of Tropical Medicine, Belgium)\*;  
 791 Paul Korrovits (Tartu University Clinics, Estonia)\*; Seppo Koskinen (National Institute for  
 792 Health and Welfare, Finland)\*; Katsuyasu Kouda (Kindai University, Japan)\*; Sudhir  
 793 Kowlessur (Ministry of Health and Quality of Life, Mauritius)\*; Slawomir Koziel (Polish  
 794 Academy of Sciences Anthropology Unit in Wroclaw, Poland)\*; Susi Kriemler (University of  
 795 Zürich, Switzerland)\*; Peter Lund Kristensen (University of Southern Denmark, Denmark)\*;  
 796 Steinar Krokstad (Norwegian University of Science and Technology, Norway)\*; Daan  
 797 Kromhout (University of Groningen, The Netherlands)\*; Herculina S Kruger (North-West  
 798 University, South Africa)\*; Ruzena Kubinova (National Institute of Public Health, Czech  
 799 Republic)\*; Renata Kuciene (Lithuanian University of Health Sciences, Lithuania)\*; Diana  
 800 Kuh (University College London, UK)\*; Urho M Kujala (University of Jyväskylä, Finland)\*;  
 801 Krzysztof Kula (Medical University of Lodz, Poland)\*; Zbigniew Kulaga (The Children's  
 802 Memorial Health Institute, Poland)\*; R Krishna Kumar (Amrita Institute of Medical Sciences,  
 803 India)\*; Pawel Kurjata (The Cardinal Wyszynski Institute of Cardiology, Poland)\*;  
 804 Yadlapalli S Kusuma (All India Institute of Medical Sciences, India)\*; Kari Kuulasmaa  
 805 (National Institute for Health and Welfare, Finland)\*; Catherine Kyobutungi (African  
 806 Population and Health Research Center, Kenya)\*; Tiina Laatikainen (National Institute for  
 807 Health and Welfare, Finland)\*; Carl Lachat (Ghent University, Belgium)\*; Tai Hing Lam  
 808 (University of Hong Kong, China)\*; Orlando Landrove (Ministerio de Salud Pública, Cuba)\*;  
 809 Vera Lanska (Institute for Clinical and Experimental Medicine, Czech Republic)\*; Georg  
 810 Lappas (Sahlgrenska Academy, Sweden)\*; Bagher Larijani (Endocrinology and Metabolism  
 811 Research Center, Iran)\*; Lars E Laugsand (Norwegian University of Science and Technology,

812 Norway)\*; Avula Laxmaiah (Indian Council of Medical Research, India)\*; Khanh Le  
 813 Nguyen Bao (National Institute of Nutrition, Vietnam)\*; Tuyen D Le (National Institute of  
 814 Nutrition, Vietnam)\*; Catherine Leclercq (Food and Agriculture Organization, Italy)\*;  
 815 Jeannette Lee (National University of Singapore, Singapore)\*; Jeonghee Lee (National  
 816 Cancer Center, South Korea)\*; Terho Lehtimäki (Tampere University Hospital, Finland)\*;  
 817 Luz M León-Muñoz (Universidad Autónoma de Madrid, Spain)\*; Naomi S Levitt (University  
 818 of Cape Town, South Africa)\*; Yanping Li (Harvard TH Chan School of Public Health,  
 819 USA)\*; Christa L Lilly (West Virginia University, USA)\*; Wei-Yen Lim (National  
 820 University of Singapore, Singapore)\*; M Fernanda Lima-Costa (Oswaldo Cruz Foundation  
 821 Rene Rachou Research Institute, Brazil)\*; Hsien-Ho Lin (National Taiwan University,  
 822 Taiwan)\*; Xu Lin (University of Chinese Academy of Sciences, China)\*; Allan Linneberg  
 823 (Research Centre for Prevention and Health, Denmark)\*; Lauren Lissner (University of  
 824 Gothenburg, Sweden)\*; Mieczyslaw Litwin (The Children's Memorial Health Institute,  
 825 Poland)\*; Jing Liu (Capital Medical University Beijing An Zhen Hospital, China)\*; Roberto  
 826 Lorbeer (University Medicine Greifswald, Germany)\*; Paulo A Lotufo (University of São  
 827 Paulo, Brazil)\*; José Eugenio Lozano (Consejería de Sanidad Junta de Castilla y León,  
 828 Spain)\*; Dalia Luksiene (Lithuanian University of Health Sciences, Lithuania)\*; Annamari  
 829 Lundqvist (National Institute for Health and Welfare, Finland)\*; Nuno Lunet (Universidade  
 830 do Porto, Portugal)\*; Per Lytsy (University of Uppsala, Sweden)\*; Guansheng Ma (Peking  
 831 University, China)\*; Jun Ma (Peking University, China)\*; George LL Machado-Coelho  
 832 (Universidade Federal de Ouro Preto, Brazil)\*; Suka Machi (The Jikei University School of  
 833 Medicine, Japan)\*; Stefania Maggi (National Research Council, Italy)\*; Dianna J Magliano  
 834 (Baker IDI Heart and Diabetes Institute, Australia)\*; Emmanuella Magriplis (Agricultural  
 835 University of Athens, Greece)\*; Marjeta Majer (University of Zagreb, Croatia)\*; Marcia  
 836 Makdisse (Hospital Israelita Albert Einstein, Brazil)\*; Reza Malekzadeh (Shiraz University

837 of Medical Sciences, Iran)\*; Rahul Malhotra (Duke-NUS Medical School, Singapore)\*;  
 838 Kodavanti Mallikharjuna Rao (Indian Council of Medical Research, India)\*; Sofia Malyutina  
 839 (Institute of Internal and Preventive Medicine, Russia)\*; Yannis Manios (Harokopio  
 840 University, Greece)\*; Jim I Mann (University of Otago, New Zealand)\*; Enzo Manzato  
 841 (University of Padova, Italy)\*; Paula Margozzini (Pontificia Universidad Católica de Chile,  
 842 Chile)\*; Pedro Marques-Vidal (Lausanne University Hospital, Switzerland)\*; Larissa P  
 843 Marques (Universidade Federal de Santa Catarina, Brazil)\*; Jaume Marrugat (Institut  
 844 Hospital del Mar d'Investigacions Mèdiques, Spain)\*; Reynaldo Martorell (Emory University,  
 845 USA)\*; Ellisiv B Mathiesen (UiT The Arctic University of Norway, Norway)\*; Alicia  
 846 Matijasevich (University of São Paulo, Brazil)\*; Tandi E Matsha (Cape Peninsula University  
 847 of Technology, South Africa)\*; Jean Claude N Mbanya (University of Yaoundé 1,  
 848 Cameroon)\*; Anselmo J Mc Donald Posso (Gorgas Memorial Institute of Health Studies,  
 849 Panama)\*; Shelly R McFarlane (The University of the West Indies, Jamaica)\*; Stephen T  
 850 McGarvey (Brown University, USA)\*; Stela McLachlan (University of Edinburgh, UK)\*;  
 851 Rachael M McLean (University of Otago, New Zealand)\*; Scott B McLean (Statistics  
 852 Canada, Canada)\*; Breige A McNulty (University College Dublin, Ireland)\*; Sounnia  
 853 Mediene-Benchekor (University of Oran 1, Algeria)\*; Jurate Medzioniene (Lithuanian  
 854 University of Health Sciences, Lithuania)\*; Aline Meirhaeghe (Institut National de la Santé  
 855 et de la Recherche Médicale, France)\*; Christa Meisinger (Helmholtz Zentrum München,  
 856 Germany)\*; Ana Maria B Menezes (Federal University of Pelotas, Brazil)\*; Geetha R Menon  
 857 (Indian Council of Medical Research, India)\*; Indrapal I Meshram (Indian Council of  
 858 Medical Research, India)\*; Andres Metspalu (University of Tartu, Estonia)\*; Haakon E  
 859 Meyer (University of Oslo, Norway)\*; Jie Mi (Capital Institute of Pediatrics, China)\*; Kairit  
 860 Mikkil (University of Tartu, Estonia)\*; Jody C Miller (University of Otago, New Zealand)\*;  
 861 Juan Francisco Miquel (Pontificia Universidad Católica de Chile, Chile)\*; J Jaime Miranda

862 (Universidad Peruana Cayetano Heredia, Peru)\*; Erkin Mirrakhimov (Kyrgyz State Medical  
 863 Academy, Kyrgyzstan)\*; Marjeta Mišigoj-Durakovic (University of Zagreb, Croatia)\*; Pietro  
 864 A Modesti (Universita' degli Studi di Firenze, Italy)\*; Mostafa K Mohamed (Ain Shams  
 865 University, Egypt)\*; Kazem Mohammad (Tehran University of Medical Sciences, Iran)\*;  
 866 Noushin Mohammadifard (Hypertension Research Center, Iran)\*; Viswanathan Mohan  
 867 (Madras Diabetes Research Foundation, India)\*; Salim Mohanna (Universidad Peruana  
 868 Cayetano Heredia, Peru)\*; Muhammad Fadhli Mohd Yusoff (Ministry of Health Malaysia,  
 869 Malaysia)\*; Niels C Møller (University of Southern Denmark, Denmark)\*; Dénes Molnár  
 870 (University of Pécs, Hungary)\*; Amirabbas Momenan (Shahid Beheshti University of  
 871 Medical Sciences, Iran)\*; Charles K Mondo (Mulago Hospital, Uganda)\*; Kotsedi Daniel K  
 872 Monyeke (University of Limpopo, South Africa)\*; Leila B Moreira (Universidade Federal do  
 873 Rio Grande do Sul, Brazil)\*; Alain Morejon (University Medical Science, Cuba)\*; Luis A  
 874 Moreno (Universidad de Zaragoza, Spain)\*; Karen Morgan (RCSI Dublin, Ireland)\*; George  
 875 Moschonis (Harokopio University, Greece)\*; Malgorzata Mossakowska (International  
 876 Institute of Molecular and Cell Biology, Poland)\*; Aya Mostafa (Ain Shams University,  
 877 Egypt)\*; Jorge Mota (University of Porto, Portugal)\*; Mohammad Esmaeel Motlagh (Ahvaz  
 878 Jundishapur University of Medical Sciences, Iran)\*; Jorge Motta (Gorgas Memorial Institute  
 879 of Public Health, Panama)\*; Thet Thet Mu (Department of Public Health, Myanmar)\*; Maria  
 880 L Muiesan (University of Brescia, Italy)\*; Martina Müller-Nurasyid (Helmholtz Zentrum  
 881 München, Germany)\*; Neil Murphy (Imperial College London, UK)\*; Jaakko Mursu  
 882 (University of Eastern Finland, Finland)\*; Vera Musil (University of Zagreb, Croatia)\*; Iraj  
 883 Nabipour (Bushehr University of Medical Sciences, Iran)\*; Gabriele Nagel (Ulm University,  
 884 Germany)\*; Balkish M Naidu (Institute of Public Health, Malaysia)\*; Harunobu Nakamura  
 885 (Kobe University, Japan)\*; Jana Námesná (Regional Authority of Public Health, Banská  
 886 Bystrica, Slovakia)\*; Ei Ei K Nang (National University of Singapore, Singapore)\*; Vinay B



887 Nangia (Suraj Eye Institute, India)\*; Sameer Narake (Healis-Sekhsaria Institute for Public  
 888 Health, India)\*; Eva Maria Navarrete-Muñoz (CIBER en Epidemiología y Salud Pública,  
 889 Spain)\*; Ndeye Coumba Ndiaye (INSERM, France)\*; William A Neal (West Virginia  
 890 University, USA)\*; Martin Neovius (Karolinska Institutet, Sweden)\*; Flavio Nervi  
 891 (Pontificia Universidad Católica de Chile, Chile)\*; Hannelore K Neuhauser (Robert Koch  
 892 Institute, Germany)\*; Chung T Nguyen (National Institute of Hygiene and Epidemiology,  
 893 Vietnam)\*; Nguyen D Nguyen (The University of Pharmacy and Medicine of Ho Chi Minh  
 894 City, Vietnam)\*; Quang Ngoc Nguyen (Hanoi Medical University, Vietnam)\*; Ramfis E  
 895 Nieto-Martínez (Miami Veterans Affairs Healthcare System, USA)\*; Teemu J Niiranen  
 896 (National Institute for Health and Welfare, Finland)\*; Guang Ning (Shanghai Jiao-Tong  
 897 University School of Medicine, China)\*; Toshiharu Ninomiya (Kyushu University, Japan)\*;  
 898 Sania Nishtar (Heartfile, Pakistan)\*; Marianna Noale (National Research Council, Italy)\*;  
 899 Oscar A Noboa (Universidad de la República, Uruguay)\*; Ahmad Ali Noorbala (Tehran  
 900 University of Medical Sciences, Iran)\*; Teresa Norat (Imperial College London, UK)\*;  
 901 Davide Noto (University of Palermo, Italy)\*; Mohannad Al Nsour (Eastern Mediterranean  
 902 Public Health Network, Jordan)\*; Dermot O'Reilly (The Queen's University of Belfast, UK)\*;  
 903 Eiji Oda (Tachikawa General Hospital, Japan)\*; Glenn Oehlers (Academic Hospital of  
 904 Paramaribo, Suriname)\*; Kyungwon Oh (Korea Centers for Disease Control and Prevention,  
 905 South Korea)\*; Kumiko Ohara (Kobe University, Japan)\*; Maria Teresa A Olinto  
 906 (Universidade do Vale do Rio dos Sinos, Brazil)\*; Isabel O Oliveira (Federal University of  
 907 Pelotas, Brazil)\*; Mohd Azahadi Omar (Ministry of Health Malaysia, Malaysia)\*; Altan Onat  
 908 (Istanbul University, Turkey)\*; Sok King Ong (Ministry of Health, Brunei)\*; Lariane M Ono  
 909 (Universidade Federal de Santa Catarina, Brazil)\*; Pedro Ordunez (Pan American Health  
 910 Organization, USA)\*; Rui Ornelas (University of Madeira, Portugal)\*; Clive Osmond (MRC  
 911 Lifecourse Epidemiology Unit, UK)\*; Sergej M Ostojic (University of Novi Sad, Serbia)\*;

912 Afshin Ostovar (Bushehr University of Medical Sciences, Iran)\*; Johanna A Otero  
 913 (Fundación Oftalmológica de Santander, Colombia)\*; Kim Overvad (Aarhus University,  
 914 Denmark)\*; Ellis Owusu-Dabo (Kwame Nkrumah University of Science and Technology,  
 915 Ghana)\*; Fred Michel Paccaud (Institute for Social and Preventive Medicine, Switzerland)\*;  
 916 Cristina Padez (University of Coimbra, Portugal)\*; Elena Pahomova (University of Latvia,  
 917 Latvia)\*; Andrzej Pajak (Jagiellonian University Medical College, Poland)\*; Domenico Palli  
 918 (Cancer Prevention and Research Institute, Italy)\*; Luigi Palmieri (Istituto Superiore di  
 919 Sanità, Italy)\*; Wen-Harn Pan (Academia Sinica, Taiwan)\*; Songhomitra Panda-Jonas  
 920 (Ruprecht-Karls-University of Heidelberg, Germany)\*; Francesco Panza (IRCCS Casa  
 921 Sollievo della Sofferenza, Italy)\*; Dimitrios Papandreou (Zayed University, UAE)\*;  
 922 Winsome R Parnell (University of Otago, New Zealand)\*; Mahboubeh Parsaeian (Tehran  
 923 University of Medical Sciences, Iran)\*; Nikhil D Patel (Jivandeep Hospital, India)\*; Ivan  
 924 Pecin (University of Zagreb School of Medicine, Croatia; University Hospital Centre Zagreb,  
 925 Croatia)\*; Mangesh S Pednekar (Healis-Sekhsaria Institute for Public Health, India)\*;  
 926 Nasheeta Peer (South African Medical Research Council, South Africa)\*; Petra H Peeters  
 927 (University Medical Center Utrecht, The Netherlands)\*; Sergio Viana Peixoto (Oswaldo  
 928 Cruz Foundation Rene Rachou Research Institute, Brazil)\*; Markku Peltonen (National  
 929 Institute for Health and Welfare, Finland)\*; Alexandre C Pereira (Heart Institute, Brazil)\*;  
 930 Annette Peters (Helmholtz Zentrum München, Germany)\*; Janina Petkeviciene (Lithuanian  
 931 University of Health Sciences, Lithuania)\*; Niloofar Peykari (Non-Communicable Diseases  
 932 Research Center, Iran)\*; Son Thai Pham (Vietnam National Heart Institute, Vietnam)\*; Iris  
 933 Pigeot (Leibniz Institute for Prevention Research and Epidemiology - BIPS, Germany)\*;  
 934 Hynek Pikhart (University College London, UK)\*; Aida Pilav (Federal Ministry of Health,  
 935 Bosnia and Herzegovina)\*; Lorenza Pilotto (Centro di Prevenzione Cardiovascolare Udine,  
 936 Italy)\*; Freda Pitakaka (Ministry of Health and Medical Services, Solomon Islands)\*;

937 Aleksandra Piwonska (The Cardinal Wyszyński Institute of Cardiology, Poland)\*; Pedro  
 938 Plans-Rubió (Public Health Agency of Catalonia, Spain)\*; Ozren Polašek (University of Split,  
 939 Croatia)\*; Miquel Porta (Institut Hospital del Mar d'Investigacions Mèdiques, Spain)\*;  
 940 Marileen LP Portegies (Erasmus Medical Center Rotterdam, The Netherlands)\*; Akram  
 941 Pourshams (Digestive Disease Research Institute, Iran)\*; Hossein Poustchi (Digestive  
 942 Disease Research Institute, Iran)\*; Rajendra Pradeepa (Madras Diabetes Research Foundation,  
 943 India)\*; Mathur Prashant (Indian Council of Medical Research, India)\*; Jacqueline F Price  
 944 (University of Edinburgh, UK)\*; Jarden J Puder (Centre Hospitalier Universitaire Vaudois,  
 945 Switzerland)\*; Maria Puiu (Victor Babes University of Medicine and Pharmacy, Romania)\*;  
 946 Margus Punab (Tartu University Clinics, Estonia)\*; Radwan F Qasrawi (Al-Quds University,  
 947 Palestine)\*; Mostafa Qorbani (Alborz University of Medical Sciences, Iran)\*; Tran Quoc Bao  
 948 (Ministry of Health, Vietnam)\*; Ivana Radic (University of Novi Sad, Serbia)\*; Ricardas  
 949 Radisauskas (Lithuanian University of Health Sciences, Lithuania)\*; Mahfuzar Rahman  
 950 (BRAC, Bangladesh)\*; Olli Raitakari (University of Turku, Finland)\*; Manu Raj (Amrita  
 951 Institute of Medical Sciences, India)\*; Sudha Ramachandra Rao (National Institute of  
 952 Epidemiology, India)\*; Ambady Ramachandran (India Diabetes Research Foundation,  
 953 India)\*; Elisabete Ramos (University of Porto Medical School, Portugal)\*; Lekhraj Rampal  
 954 (Universiti Putra Malaysia, Malaysia)\*; Sanjay Rampal (University of Malaya, Malaysia)\*;  
 955 Daniel A Rangel Reina (Gorgas Memorial Institute of Health Studies, Panama)\*; Josep  
 956 Redon (University of Valencia, Spain)\*; Paul Ferdinand M Reganit (University of the  
 957 Philippines, Philippines)\*; Robespierre Ribeiro (Minas Gerais State Secretariat for Health,  
 958 Brazil)\*; Elio Riboli (Imperial College London, UK)\*; Fernando Rigo (Health Center San  
 959 Agustín, Spain)\*; Tobias F Rinke de Wit (PharmAccess Foundation, The Netherlands)\*;  
 960 Raphael M Ritti-Dias (Hospital Israelita Albert Einstein, Brazil)\*; Sian M Robinson  
 961 (University of Southampton, UK)\*; Cynthia Robitaille (Public Health Agency of Canada,

962 Canada)\*; Fernando Rodríguez-Artalejo (Universidad Autónoma de Madrid, Spain)\*; María  
 963 del Cristo Rodríguez-Perez (Canarian Health Service, Spain)\*; Laura A Rodríguez-  
 964 Villamizar (Universidad Industrial de Santander, Colombia)\*; Rosalba Rojas-Martinez  
 965 (Instituto Nacional de Salud Pública, Mexico)\*; Dora Romaguera (CIBEROBN, Spain)\*;  
 966 Kimmo Ronkainen (University of Eastern Finland, Finland)\*; Annika Rosengren (University  
 967 of Gothenburg, Sweden)\*; Joel GR Roy (Statistics Canada, Canada)\*; Adolfo Rubinstein  
 968 (Institute for Clinical Effectiveness and Health Policy, Argentina)\*; Blanca Sandra Ruiz-  
 969 Betancourt (Instituto Mexicano del Seguro Social, Mexico)\*; Marcin Rutkowski (Medical  
 970 University of Gdansk, Poland)\*; Charumathi Sabanayagam (Singapore Eye Research  
 971 Institute, Singapore)\*; Harshpal S Sachdev (Sitaram Bhartia Institute of Science and  
 972 Research, India)\*; Olfa Saidi (University Tunis El Manar, Tunisia)\*; Sibel Sakarya  
 973 (Marmara University, Turkey)\*; Benoit Salanave (French Public Health Agency, France)\*;  
 974 Eduardo Salazar Martinez (National Institute of Public Health, Mexico)\*; Diego Salmerón  
 975 (CIBER de Epidemiología y Salud Pública, Spain)\*; Veikko Salomaa (National Institute for  
 976 Health and Welfare, Finland)\*; Jukka T Salonen (University of Helsinki, Finland)\*; Massimo  
 977 Salvetti (University of Brescia, Italy)\*; Jose Sánchez-Abanto (National Institute of Health,  
 978 Peru)\*; Susana Sans (Catalan Department of Health, Spain)\*; Diana A Santos (Universidade  
 979 de Lisboa, Portugal)\*; Ina S Santos (Federal University of Pelotas, Brazil)\*; Renata Nunes  
 980 dos Santos (University of Sao Paulo Clinics Hospital, Brazil)\*; Rute Santos (University of  
 981 Porto, Portugal)\*; Jouko L Saramies (South Karelia Social and Health Care District,  
 982 Finland)\*; Luis B Sardinha (Universidade de Lisboa, Portugal)\*; Giselle Sarganas(Robert  
 983 Koch Institute, Germany)\*; Nizal Sarrafzadegan (Isfahan Cardiovascular Research Center,  
 984 Iran)\*; Kai-Uwe Saum (German Cancer Research Center, Germany)\*; Savvas Savva  
 985 (Research and Education Institute of Child Health, Cyprus)\*; Marcia Scazufca (University of  
 986 Sao Paulo Clinics Hospital, Brazil)\*; Herman Schargrotsky (Hospital Italiano de Buenos

987 Aires, Argentina)\*; Constance Schultsz (Academic Medical Center of University of  
 988 Amsterdam, The Netherlands)\*; Aletta E Schutte (South African Medical Research Council,  
 989 South Africa; North-West University, South Africa)\*; Aye Aye Sein (Ministry of Health,  
 990 Myanmar)\*; Abhijit Sen (Norwegian University of Science and Technology, Norway)\*;  
 991 Idowu O Senbanjo (Lagos State University College of Medicine, Nigeria)\*; Sadaf G  
 992 Sepanlou (Tehran University of Medical Sciences, Iran)\*; Sanjib K Sharma (B P Koirala  
 993 Institute of Health Sciences, Nepal)\*; Jonathan E Shaw (Baker IDI Heart and Diabetes  
 994 Institute, Australia)\*; Kenji Shibuya (The University of Tokyo, Japan)\*; Dong Wook Shin  
 995 (Samsung Medical Center, South Korea)\*; Youchan Shin (Singapore Eye Research Institute,  
 996 Singapore)\*; Rosalynn Siantar (Singapore Eye Research Institute, Singapore)\*; Abla M Sibai  
 997 (American University of Beirut, Lebanon)\*; Diego Augusto Santos Silva (Federal University  
 998 of Santa Catarina, Brazil)\*; Mary Simon (India Diabetes Research Foundation, India)\*;  
 999 Judith Simons (St Vincent's Hospital, Australia)\*; Leon A Simons (University of New South  
 1000 Wales, Australia)\*; Michael Sjöström (Karolinska Institutet, Sweden)\*; Sine Skovbjerg  
 1001 (Research Centre for Prevention and Health, Denmark)\*; Jolanta Slowikowska-Hilczer  
 1002 (Medical University of Lodz, Poland)\*; Przemyslaw Slusarczyk (International Institute of  
 1003 Molecular and Cell Biology, Poland)\*; Liam Smeeth (London School of Hygiene & Tropical  
 1004 Medicine, UK)\*; Margaret C Smith (University of Oxford, UK)\*; Marieke B Snijder  
 1005 (Academic Medical Center Amsterdam, The Netherlands)\*; Hung-Kwan So (The Chinese  
 1006 University of Hong Kong, China)\*; Eugène Sobngwi (University of Yaoundé 1, Cameroon)\*;  
 1007 Stefan Söderberg (Umeå University, Sweden)\*; Vincenzo Solfrizzi (University of Bari,  
 1008 Italy)\*; Emily Sonestedt (Lund University, Sweden)\*; Yi Song (Peking University, China)\*;  
 1009 Thorkild IA Sørensen (University of Copenhagen, Denmark)\*; Maroje Soric (University of  
 1010 Zagreb, Croatia)\*; Charles Sossa Jérôme (Institut Régional de Santé Publique, Benin)\*;  
 1011 Aicha Soumare (University of Bordeaux, France)\*; Jan A Staessen (University of Leuven,

1012 Belgium)\*; Gregor Starc (University of Ljubljana, Slovenia)\*; Maria G Stathopoulou  
 1013 (INSERM, France)\*; Bill Stavreski (Heart Foundation, Australia)\*; Jostein Steene-  
 1014 Johannessen (Norwegian School of Sport Sciences, Norway)\*; Peter Stehle (Bonn University,  
 1015 Germany)\*; Aryeh D Stein (Emory University, USA)\*; George S Stergiou (Sotiria Hospital,  
 1016 Greece)\*; Jochanan Stessman (Hadassah University Medical Center, Israel)\*; Jutta Stieber  
 1017 (Helmholtz Zentrum München, Germany; deceased)\*; Doris Stöckl (Helmholtz Zentrum  
 1018 München, Germany)\*; Tanja Stocks (Lund University, Sweden)\*; Jakub Stokwiszewski  
 1019 (National Institute of Public Health-National Institute of Hygiene, Poland)\*; Karien Stronks  
 1020 (University of Amsterdam, The Netherlands)\*; Maria Wany Strufaldi (Federal University of  
 1021 São Paulo, Brazil)\*; Chien-An Sun (Fu Jen Catholic University, Taiwan)\*; Johan Sundström  
 1022 (Uppsala University, Sweden)\*; Yn-Tz Sung (The Chinese University of Hong Kong,  
 1023 China)\*; Paibul Suriyawongpaisal (Mahidol University, Thailand)\*; Rody G Sy (University  
 1024 of the Philippines, Philippines)\*; E Shyong Tai (National University of Singapore,  
 1025 Singapore)\*; Mari-Liis Tammesoo (University of Tartu, Estonia)\*; Abdonas Tamosiunas  
 1026 (Lithuanian University of Health Sciences, Lithuania)\*; Eng Joo Tan (University of Sydney,  
 1027 Australia)\*; Line Tang (Research Centre for Prevention and Health, Denmark)\*; Xun Tang  
 1028 (Peking University, China)\*; Frank Tanser (University of KwaZulu-Natal, South Africa)\*;  
 1029 Yong Tao (Peking University, China)\*; Mohammed Rasoul Tarawneh (Ministry of Health,  
 1030 Jordan)\*; Carolina B Tarqui-Mamani (National Institute of Health, Peru)\*; Oana-Florentina  
 1031 Tautu (Carol Davila University of Medicine and Pharmacy, Romania)\*; Anne Taylor (The  
 1032 University of Adelaide, Australia)\*; Holger Theobald (Karolinska Institutet, Sweden)\*;  
 1033 Lutgarde Thijs (University of Leuven, Belgium)\*; Betina H Thuesen (Research Centre for  
 1034 Prevention and Health, Denmark)\*; Anne Tjonneland (Danish Cancer Society Research  
 1035 Centre, Denmark)\*; Hanna K Tolonen (National Institute for Health and Welfare, Finland)\*;  
 1036 Janne S Tolstrup (University of Southern Denmark, Denmark)\*; Murat Topbas (Karadeniz

1037 Technical University, Turkey)\*; Roman Topór-Madry (Jagiellonian University Medical  
 1038 College, Poland)\*; María José Tormo (Health Service of Murcia, Spain)\*; Maties Torrent  
 1039 (IB-SALUT Area de Salut de Menorca, Spain)\*; Pierre Traissac (Institut de Recherche pour  
 1040 le Développement, France)\*; Dimitrios Trichopoulos (Harvard TH Chan School of Public  
 1041 Health, USA; deceased)\*; Antonia Trichopoulou (Hellenic Health Foundation, Greece)\*;  
 1042 Oanh TH Trinh (The University of Pharmacy and Medicine of Ho Chi Minh City, Vietnam)\*;  
 1043 Atul Trivedi (Government Medical College, India)\*; Lechaba Tshepo (Sefako Makgatho  
 1044 Health Science University, South Africa)\*; Marshall K Tulloch-Reid (The University of the  
 1045 West Indies, Jamaica)\*; Fikru Tullu (Addis Ababa University, Ethiopia)\*; Tomi-Pekka  
 1046 Tuomainen (University of Eastern Finland, Finland)\*; Jaakko Tuomilehto (Dasman Diabetes  
 1047 Institute, Kuwait)\*; Maria L Turley (Ministry of Health, New Zealand)\*; Per Tynelius  
 1048 (Karolinska Institutet, Sweden)\*; Christophe Tzourio (University of Bordeaux, France)\*;  
 1049 Peter Ueda (Harvard TH Chan School of Public Health, USA)\*; Eunice E Ugel (Universidad  
 1050 Centro-Occidental Lisandro Alvarado, Venezuela)\*; Hanno Ulmer (Medical University of  
 1051 Innsbruck, Austria)\*; Hannu MT Uusitalo (University of Tampere Tays Eye Center,  
 1052 Finland)\*; Gonzalo Valdivia (Pontificia Universidad Católica de Chile, Chile)\*; Damaskini  
 1053 Valvi (Harvard TH Chan School of Public Health, USA)\*; Yvonne T van der Schouw  
 1054 (University Medical Center Utrecht, The Netherlands)\*; Koen Van Herck (Ghent University,  
 1055 Belgium)\*; Hoang Van Minh (Hanoi School of Public Health, Vietnam)\*; Lenie van Rossem  
 1056 (University Medical Center Utrecht, The Netherlands)\*; Natasja M Van Schoor (Amsterdam  
 1057 Public Health Institute, The Netherlands)\*; Irene GM van Valkengoed (Academic Medical  
 1058 Center Amsterdam, The Netherlands)\*; Dirk Vanderschueren (Katholieke Universiteit  
 1059 Leuven, Belgium)\*; Diego Vanuzzo (Centro di Prevenzione Cardiovascolare Udine, Italy)\*;  
 1060 Lars Vatten (Norwegian University of Science and Technology, Norway)\*; Tomas Vega  
 1061 (Consejería de Sanidad Junta de Castilla y León, Spain)\*; Gustavo Velasquez-Melendez

1062 (Universidade Federal de Minas Gerais, Brazil)\*; Giovanni Veronesi (University of Insubria,  
 1063 Italy)\*; WM Monique Verschuren (National Institute for Public Health and the Environment,  
 1064 The Netherlands)\*; Roosmarijn Verstraeten (Institute of Tropical Medicine, Belgium)\*;  
 1065 Cesar G Victora (Federal University of Pelotas, Brazil)\*; Lucie Viet (National Institute for  
 1066 Public Health and the Environment, The Netherlands)\*; Eira Viikari-Juntura (Finnish  
 1067 Institute of Occupational Health, Finland)\*; Paolo Vineis (Imperial College London, UK)\*;  
 1068 Jesus Vioque (Universidad Miguel Hernandez, Spain)\*; Jyrki K Virtanen (University of  
 1069 Eastern Finland, Finland)\*; Sophie Visvikis-Siest (INSERM, France)\*; Bharathi  
 1070 Viswanathan (Ministry of Health, Seychelles)\*; Tiina Vlasoff (North Karelian Center for  
 1071 Public Health, Finland)\*; Peter Vollenweider (Lausanne University Hospital, Switzerland)\*;  
 1072 Sari Voutilainen (University of Eastern Finland, Finland)\*; Alisha N Wade (University of the  
 1073 Witwatersrand, South Africa)\*; Aline Wagner (University of Strasbourg, France)\*; Janette  
 1074 Walton (University College Cork, Ireland)\*; Wan Mohamad Wan Bebakar (Universiti Sains  
 1075 Malaysia, Malaysia)\*; Wan Nazaimoon Wan Mohamud (Institute for Medical Research,  
 1076 Malaysia)\*; Rildo S Wanderley Jr. (University of Pernambuco, Brazil)\*; Ming-Dong Wang  
 1077 (Public Health Agency of Canada, Canada)\*; Qian Wang (Xinjiang Medical University,  
 1078 China)\*; Ya Xing Wang (Capital Medical University, China)\*; Ying-Wei Wang (Ministry of  
 1079 Health and Welfare, Taiwan)\*; S Goya Wannamethee (University College London, UK)\*;  
 1080 Nicholas Wareham (University of Cambridge, UK)\*; Niels Wedderkopp (University of  
 1081 Southern Denmark, Denmark)\*; Deepa Weerasekera (Ministry of Health, New Zealand)\*;  
 1082 Peter H Whincup (St George's, University of London, UK)\*; Kurt Widhalm (Medical  
 1083 University of Vienna, Austria)\*; Indah S Widyahening (Universitas Indonesia, Indonesia)\*;  
 1084 Andrzej Wiecek (Medical University of Silesia, Poland)\*; Alet H Wijga (National Institute  
 1085 for Public Health and the Environment, The Netherlands)\*; Rainford J Wilks (The University  
 1086 of the West Indies, Jamaica)\*; Johann Willeit (Medical University of Innsbruck, Austria)\*;



1087 Peter Willeit (Medical University of Innsbruck, Austria)\*; Emmanuel A Williams (Komfo  
 1088 Anokye Teaching Hospital, Ghana)\*; Tom Wilsgaard (UiT The Arctic University of Norway,  
 1089 Norway)\*; Bogdan Wojtyniak (National Institute of Public Health-National Institute of  
 1090 Hygiene, Poland)\*; Roy A Wong-McClure (Caja Costarricense de Seguro Social, Costa  
 1091 Rica)\*; Tien Yin Wong (Duke-NUS Medical School, Singapore)\*; Jean Woo (The Chinese  
 1092 University of Hong Kong, China)\*; Mark Woodward (University of New South Wales,  
 1093 Australia; University of Oxford, UK)\*; Aleksander Giwercman Wu (Lund University,  
 1094 Sweden)\*; Frederick C Wu (University of Manchester, UK)\*; Shouling Wu (Kailuan General  
 1095 Hospital, China)\*; Haiquan Xu (Institute of Food and Nutrition Development of Ministry of  
 1096 Agriculture, China)\*; Weili Yan (Children's Hospital of Fudan University, China)\*;  
 1097 Xiaoguang Yang (Chinese Center for Disease Control and Prevention, China)\*; Xingwang  
 1098 Ye (University of Chinese Academy of Sciences, China)\*; Panayiotis K Yiallourous  
 1099 (University of Cyprus, Cyprus)\*; Akihiro Yoshihara (Niigata University, Japan)\*; Novie O  
 1100 Younger-Coleman (The University of the West Indies, Jamaica)\*; Ahmad F Yusoff (Ministry  
 1101 of Health Malaysia, Malaysia)\*; Muhammad Fadhli M Yusoff (Institute of Public Health,  
 1102 Malaysia)\*; Sabina Zambon (University of Padova, Italy)\*; Antonis Zampelas (Agricultural  
 1103 University of Athens, Greece)\*; Tomasz Zdrojewski (Medical University of Gdansk,  
 1104 Poland)\*; Yi Zeng (Duke University, USA; Peking University, China, USA)\*; Dong Zhao  
 1105 (Capital Medical University Beijing An Zhen Hospital, China)\*; Wenhua Zhao (Chinese  
 1106 Center for Disease Control and Prevention, China)\*; Wei Zheng (Vanderbilt University,  
 1107 USA)\*; Yingfeng Zheng (Singapore Eye Research Institute, Singapore)\*; Dan Zhu (Inner  
 1108 Mongolia Medical University, China)\*; Baurzhan Zhussupov (Kazakh National Medical  
 1109 University, Kazakhstan)\*; Esther Zimmermann (Bispebjerg and Frederiksberg Hospitals,  
 1110 Denmark)\*; Julio Zuñiga Cisneros (Gorgas Memorial Institute of Public Health, Panama)\*